Under the agreement, Antibodies by Design, of Martinsried, and JPT, a subsidiary of Berlin-based Jerini, will offer each other's products and services to customers worldwide, except for
Antibodies by Design develops monoclonal antibodies, while JPT offer complementary peptide-based services and products.